| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Nauck, Birgit Wilhel. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?] MMW Fortschritte der Medizin. vol 159. issue Suppl 5. 2019-08-02. PMID:28643293. |
[why is a combination of basal insulin with a glp-1 receptor agonist useful in many patients with type 2 diabetes?] |
2019-08-02 |
2023-08-13 |
Not clear |
| Michael Nauck, Birgit Wilhel. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?] MMW Fortschritte der Medizin. vol 159. issue Suppl 5. 2019-08-02. PMID:28643293. |
in 2015, the combination of basal insulin and glp-1 receptor agonist (ra) was incorporated into the guideline recommendations for type 2 diabetes as an option for the last escalation step. |
2019-08-02 |
2023-08-13 |
Not clear |
| Michael Nauck, Birgit Wilhel. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?] MMW Fortschritte der Medizin. vol 159. issue Suppl 5. 2019-08-02. PMID:28643293. |
basal insulin is predominantly active between meals and in the fasting state, whereas the main action of glp-1 ra consists in preventing an excessive postprandial blood glucose increase. |
2019-08-02 |
2023-08-13 |
Not clear |
| Michael Nauck, Birgit Wilhel. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?] MMW Fortschritte der Medizin. vol 159. issue Suppl 5. 2019-08-02. PMID:28643293. |
unlike glp-1 ra, no upper dose limits are defined for basal insulin. |
2019-08-02 |
2023-08-13 |
Not clear |
| Michael Nauck, Birgit Wilhel. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?] MMW Fortschritte der Medizin. vol 159. issue Suppl 5. 2019-08-02. PMID:28643293. |
therefore, patients achieving their treatment goals with glp-1 ra alone are better treated without insulin. |
2019-08-02 |
2023-08-13 |
Not clear |
| Mariana Rodrigues Davanso, Carolina Caliari-Oliveira, Carlos Eduardo Barra Couri, Dimas Tadeu Covas, Angela Merice de Oliveira Leal, Júlio César Voltarelli, Kelen Cristina Ribeiro Malmegrim, Juliana Navarro Ueda Yaochit. DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes. Inflammation. vol 42. issue 2. 2019-08-02. PMID:30707388. |
diabetes incidence, insulin, glucagon, glucagon-like peptide-1 (glp-1) serum levels, and inflammatory cytokine levels were quantified in pancreas homogenate after 30 and 90 days of treatment. |
2019-08-02 |
2023-08-13 |
mouse |
| Mariana Rodrigues Davanso, Carolina Caliari-Oliveira, Carlos Eduardo Barra Couri, Dimas Tadeu Covas, Angela Merice de Oliveira Leal, Júlio César Voltarelli, Kelen Cristina Ribeiro Malmegrim, Juliana Navarro Ueda Yaochit. DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes. Inflammation. vol 42. issue 2. 2019-08-02. PMID:30707388. |
idpp-4 decreased blood glucose level while increased glp-1 and insulin levels. |
2019-08-02 |
2023-08-13 |
mouse |
| Fernando Gomez-Peralta, Cristina Abre. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. Drug design, development and therapy. vol 13. 2019-07-31. PMID:30863012. |
glucagon-like peptide 1 (glp-1) receptor agonists (glp-1 ra) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. |
2019-07-31 |
2023-08-13 |
Not clear |
| Ankit Shah, Marlena M Holter, Fatima Rimawi, Victoria Mark, Roxanne Dutia, James McGinty, Bruce Levin, Blandine Laferrèr. Insulin Clearance After Oral and Intravenous Glucose Following Gastric Bypass and Gastric Banding Weight Loss. Diabetes care. vol 42. issue 2. 2019-07-24. PMID:30523032. |
we hypothesized that the improvement in insulin clearance rates (icrs) under fasting conditions and in response to oral and intravenous (iv) glucose would improve similarly after roux-en-y gastric bypass (rygb) and adjustable gastric banding (agb) as a function of weight loss; the difference in icr after oral and iv glucose stimulation will be enhanced after rygb compared with agb, an effect mediated by glucagon-like peptide 1 (glp-1). |
2019-07-24 |
2023-08-13 |
Not clear |
| Ki-Suk Kim, In-Seung Lee, Kang-Hoon Kim, Jiyoung Park, Yumi Kim, Jeong-Hee Choi, Jin-Sung Choi, Hyeung-Jin Jan. Activation of intestinal olfactory receptor stimulates glucagon-like peptide-1 secretion in enteroendocrine cells and attenuates hyperglycemia in type 2 diabetic mice. Scientific reports. vol 7. issue 1. 2019-07-18. PMID:29070885. |
in a type 2 diabetes mellitus mouse model (db/db), oral administration of geraniol improved glucose homeostasis by increasing plasma glp-1 and insulin levels. |
2019-07-18 |
2023-08-13 |
mouse |
| Stéphane Dalle, Safia Costes, Gyslaine Bertrand, Magalie A Ravie. Methods to Study Roles of β-Arrestins in the Regulation of Pancreatic β-Cell Function. Methods in molecular biology (Clifton, N.J.). vol 1957. 2019-07-18. PMID:30919365. |
novel findings reveal important functional roles for β-arrestin 1 and β-arrestin 2 in the regulation of insulin secretion, β-cell survival, and β-cell mass plasticity not only by glucose but also by g-protein-coupled receptors, such as the glucagon-like peptide-1 (glp-1) and the pituitary adenylate cyclase-activating polypeptide (pacap) receptors or gpr40, or tyrosine kinase receptors, such as the insulin receptor. |
2019-07-18 |
2023-08-13 |
mouse |
| Masahiro Kawatani, Yuichiro Yamada, Masahito Kawatan. Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons. Peptides. vol 107. 2019-07-15. PMID:30081042. |
glp-1 related drugs, such as liraglutide, are widely used to treat diabetic patients and work by stimulating pancreatic β cells to increase glucose-dependent insulin secretion. |
2019-07-15 |
2023-08-13 |
mouse |
| Hidayat Hussain, Ghulam Abbas, Ivan R Green, Iftikhar Al. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018). Expert opinion on therapeutic patents. vol 29. issue 7. 2019-07-12. PMID:31203700. |
dipeptidyl peptidase 4 (dpp-4) belongs to the family of serine proteases and is involved in the degradation of glp-1 and gip hormones, which enhance the production and release of insulin. |
2019-07-12 |
2023-08-13 |
Not clear |
| Peter Almgren, Andreas Lindqvist, Ulrika Krus, Liisa Hakaste, Emilia Ottosson-Laakso, Olof Asplund, Emily Sonestedt, Rashmi B Prasad, Esa Laurila, Marju Orho-Melander, Olle Melander, Tiinamaija Tuomi, Jens Juul Holst, Peter M Nilsson, Nils Wierup, Leif Groop, Emma Ahlqvis. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI insight. vol 2. issue 21. 2019-07-10. PMID:29093273. |
the secretion of insulin and glucagon from the pancreas and the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) from the gastrointestinal tract is essential for glucose homeostasis. |
2019-07-10 |
2023-08-13 |
human |
| Peter Almgren, Andreas Lindqvist, Ulrika Krus, Liisa Hakaste, Emilia Ottosson-Laakso, Olof Asplund, Emily Sonestedt, Rashmi B Prasad, Esa Laurila, Marju Orho-Melander, Olle Melander, Tiinamaija Tuomi, Jens Juul Holst, Peter M Nilsson, Nils Wierup, Leif Groop, Emma Ahlqvis. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI insight. vol 2. issue 21. 2019-07-10. PMID:29093273. |
in order to identify new potential therapeutic targets for treatment of t2d, we performed a meta-analysis of a gwas and an exome-wide association study of circulating insulin, glucagon, gip, and glp-1 concentrations measured during an oral glucose tolerance test in up to 7,828 individuals. |
2019-07-10 |
2023-08-13 |
human |
| Paul M Ryan, Elaine Patterson, Robert M Kent, Helena Stack, Paula M O'Connor, Kiera Murphy, Veronica L Peterson, Rupasri Mandal, David S Wishart, Timothy G Dinan, John F Cryan, Randy J Seeley, Catherine Stanton, R Paul Ros. Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents. Scientific reports. vol 7. issue 1. 2019-06-28. PMID:29051554. |
conversely, extended glp-1 microbe intervention improved glucose-dependent insulin secretion, glucose metabolism and cholesterol metabolism, compared to the high-fat control group. |
2019-06-28 |
2023-08-13 |
rat |
| Line Engelbrechtsen, Yuvaraj Mahendran, Anna Jonsson, Anette Prior Gjesing, Peter E Weeke, Marit E Jørgensen, Kristine Færch, Daniel R Witte, Jens J Holst, Torben Jørgensen, Niels Grarup, Oluf Pedersen, Henrik Vestergaard, Signe Torekov, Jørgen K Kanters, Torben Hanse. Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. BMC genetics. vol 19. issue 1. 2019-06-28. PMID:29548277. |
subsequently, we aimed to evaluate the effect of two common gain-of-function variants in herg (rs36210421 and rs1805123) on qt interval and plasma levels of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), insulin and glucagon during an oral glucose tolerance test (ogtt). |
2019-06-28 |
2023-08-13 |
human |
| Line Engelbrechtsen, Yuvaraj Mahendran, Anna Jonsson, Anette Prior Gjesing, Peter E Weeke, Marit E Jørgensen, Kristine Færch, Daniel R Witte, Jens J Holst, Torben Jørgensen, Niels Grarup, Oluf Pedersen, Henrik Vestergaard, Signe Torekov, Jørgen K Kanters, Torben Hanse. Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. BMC genetics. vol 19. issue 1. 2019-06-28. PMID:29548277. |
the danish addition-pro cohort was used (n = 1329) to study genetic associations with levels of glp-1, gip, insulin and glucagon during an ogtt. |
2019-06-28 |
2023-08-13 |
human |
| Hartmut Ruetten, Mathias Gebauer, Ralph H Raymond, Roberto A Calle, Claudio Cobelli, Atalanta Ghosh, R Paul Robertson, Sudha S Shankar, Myrlene A Staten, Darko Stefanovski, Adrian Vella, Kathryn Wright, David A Frybur. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function. Metabolic syndrome and related disorders. vol 16. issue 8. 2019-06-26. PMID:30117761. |
the aims of this study were to 1. define the responses of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), glucagon, and peptide yy (pyy) to an oral meal and to intravenous l-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. |
2019-06-26 |
2023-08-13 |
Not clear |
| A J Schee. [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)]. Revue medicale de Liege. vol 74. issue 2. 2019-06-25. PMID:30793566. |
suliqua® (iglarlixi) is a fixed ratio combination of basal insulin glargine u100 and the glucagon-like peptide-1 (glp-1) receptor agonist lixisenatide. |
2019-06-25 |
2023-08-13 |
Not clear |